Whereas in various NASH animal models, saroglitazar treatment showed a significant reduction in ALT and histologically improved steatosis, inflammation, ballooning and fibrosis in the liver [6, 7]. Here, GPT is linked to metabolic dysfunction-associated steatohepatitis.